According to Repligen
's latest financial reports the company has $1.97 B in net assets.
A companyโs net assets is the sum of its assets minus the sum of its liabilities.
Year | Net assets | Change |
---|---|---|
2023-12-31 | $1.97 B | 3.17% |
2022-12-31 | $1.91 B | 9.18% |
2021-12-31 | $1.75 B | 14.45% |
2020-12-31 | $1.52 B | 44.29% |
2019-12-31 | $1.05 B | 72.16% |
2018-12-31 | $0.61 B | 4.06% |
2017-12-31 | $0.59 B | 250.52% |
2016-12-31 | $0.16 B | 37.49% |
2015-12-31 | $0.12 B | 9.86% |
2014-12-31 | $0.11 B | 7.55% |
2013-12-31 | $0.10 B | 23.49% |
2012-12-31 | $84.12 M | |
2011-03-31 | $67.08 M | 1.46% |
2010-03-31 | $66.12 M | -4.34% |
2009-03-31 | $69.12 M | 7.83% |
2008-03-31 | $64.1 M | 151.02% |
2007-03-31 | $25.53 M | 0.41% |
2006-03-31 | $25.43 M | 4.71% |
2005-03-31 | $24.28 M | -10.58% |
2004-03-31 | $27.16 M | 10.65% |
2003-03-31 | $24.54 M | -7.17% |
2002-03-31 | $26.44 M | -14.39% |
2001-03-31 | $30.89 M |
Company | Net assets | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $89.28 B | 4,429.63% | ๐บ๐ธ USA |
Thermo Fisher Scientific TMO | $46.84 B | 2,276.32% | ๐บ๐ธ USA |
General Electric GE | $28.58 B | 1,349.88% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $29.48 B | 1,395.79% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | $82.88 M | -95.80% | ๐บ๐ธ USA |
Novavax NVAX | -$0.72 B | -136.37% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | $2.23 B | 13.23% | ๐บ๐ธ USA |
Bio-Techne TECH | $1.96 B | -0.39% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $4.95 B | 151.19% | ๐บ๐ธ USA |
Charles River Laboratories
CRL | $3.65 B | 85.62% | ๐บ๐ธ USA |